Trinity Biotech annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Trinity Biotech Stock-Based Compensation Growth & History (TRIB)
Trinity Biotech's stock-based compensation was $324,000 for fiscal 2025.
View full Trinity Biotech company overviewTrinity Biotech annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $324,000 | −$992,000 | −75.38% |
| 2024 | 2024-12-31 | $1.3M | −$753,000 | −36.39% |
| 2023 | 2023-12-31 | $2.1M | $314,000 | +17.89% |
| 2022 | 2022-12-31 | $1.8M | $655,000 | +59.55% |
| 2021 | 2021-12-31 | $1.1M | $308,000 | +38.89% |
| 2020 | 2020-12-31 | $792,000 | $34,000 | +4.49% |
| 2019 | 2019-12-31 | $758,000 | −$611,000 | −44.63% |
| 2018 | 2018-12-31 | $1.4M | $441,000 | +47.52% |
| 2017 | 2017-12-31 | $928,000 | −$486,000 | −34.37% |
| 2016 | 2016-12-31 | $1.4M | −$136,000 | −8.77% |
| 2015 | 2015-12-31 | $1.6M | — | — |
Trinity Biotech quarterly stock-based compensation
Q2.17
Q2.18
Q4.24
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $140,000 | — | — |
| Q2 2018 | 2018-06-30 | $329,000 | $199,000 | +153.08% |
| Q2 2017 | 2017-06-30 | $130,000 | — | — |
Trinity Biotech stock-based compensation trends
Over the last five fiscal years, Trinity Biotech's stock-based compensation decreased from $792,000 to $324,000, a change of −$468,000. The latest reported quarter, Q4 2024, shows $140,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Trinity Biotech source filings ↗